Celmatix

Celmatix is a women's health biotech company pioneering ovarian health therapeutics that translate advances in female biology into novel drug candidates. The company's discovery portfolio, recently acquired by Gedeon Richter, includes a first-in-class oral FSH receptor agonist with the potential to transform fertility care through patient-friendly ovarian stimulation, a novel JNK inhibitor representing a non-hormonal immunotherapy approach for endometriosis targeting pain and inflammation, and early-stage AMH-targeting antibodies designed to expand control over ovarian folliculogenesis. Celmatix also received a $3.5M award from ARPA-H's Sprint for Women's Health and has nominated lead compounds in its oral fertility drug program. The company leverages DNA-Encoded Chemistry Technology (DEC-Tec) platforms in partnership with Baylor College of Medicine. Founded in 2009 and headquartered in New York City, Celmatix has raised approximately $24.9M in Series C funding from investors including Topspin Consumer Partners, Partnership for New York City, and Lauder Partners.